top of page

Tired of endless webinars, spamming newsletters and cold calls after a subscription?

Take a rest. Enjoy at your pace. Enjoy 


We won't disturb you.


In this article, potential Pharma 4.0™ technological solutions that can enhance continuous process verification (CPV) 4.0 are discussed. The necessary paradigm shift will allow companies to predict deviations more accurately, perform root cause analysis (RCA), ensure data integrity and GxP compliance, and ultimately be more competitive in a highly regulated industry.

Sanofi’s $400 million (approx. €364 million) investment in Research and Development, biologics manufacturing and production improvements means all manufacturing stages are controlled through state-of-the-art analytical techniques that forecast and avoid variations to improve performance and ensure quality. Plant operators are supported by digital collaboration, data analytics or augmented reality solutions, helping them to make real-time decisions and adjustments, while simulations provide the level of manufacturing modularity and flexibility required to support personalized medicines.

bottom of page